B-cell Lymphomas (original) (raw)
Latest News for: b-cell lymphomas
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (Genmab A/S)
Public Technologies 13 Jun 2026
2026-06-13 18.45.00 CEST Genmab A/S - Investor News Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at
Hastings Tribune 11 Jun 2026
-- Single dose of vispa-cel produced durable responses in 2L LBCL patients. 82% ORR, 67% CR rate, and 17.1-month mPFS -- ... .
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
Nasdaq Globe Newswire 11 Jun 2026
-- Single dose of vispa-cel produced durable ...
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 (Form 8-K) (Caribou Biosciences Inc)
Public Technologies 11 Jun 2026
) Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 ... Sixty-three second-line large B cell lymphoma (2L LBCL) patients received a single dose of vispa-cel during dose expansion.
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
News-Press Now 04 Jun 2026
Company evaluating systemic ...
Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
PR Newswire 04 Jun 2026
LP-168) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) who have received at least two prior systemic therapies, including BTK inhibitors ... Cell Lymphoma.
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Form 8-K) (ADC Therapeutics SA)
Public Technologies 03 Jun 2026
... after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma.
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
PR Newswire 03 Jun 2026
... after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma.
Mantle Cell Lymphoma Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the ...
GetNews 02 Jun 2026
Company Name Inactive Products Mantle Cell Lymphoma Key Companies Mantle Cell Lymphoma Key Products Mantle Cell Lymphoma- Unmet Needs Mantle Cell Lymphoma- Market Drivers and Barriers Mantle Cell ...
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Expands as 22+ Companies Driving Innovation in the Therapeutics ...
GetNews 30 May 2026
ONO-4685 is an investigational anti-PD-1/CD3 bispecific antibody being developed by Ono Pharmaceutical for relapsed or refractory T-cell lymphomas, including Cutaneous T-cell Lymphoma (CTCL).
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Shows Potential with Active Contributions from 22+ Key Companies ...
GetNews 29 May 2026
Company Name Inactive Products Cutaneous T-cell lymphoma Key Companies Cutaneous T-cell lymphoma Key Products Cutaneous T-cell lymphoma- Unmet Needs Cutaneous T-cell lymphoma- Market Drivers and ...
T-Cell Lymphoma Treatment Pipeline Witnesses Robust Growth with 90+ Companies Advancing Novel Therapeutics | DelveInsight
GetNews 29 May 2026
... lymphoma/leukemia, Peripheral T-cell lymphomas, Cutaneous T-cell lymphomas, Adult T-cell leukemia/lymphoma, Anaplastic Large Cell Lymphoma, and Angioimmunoblastic T-Cell Lymphoma, among others.
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
PR Newswire 28 May 2026
... T-cell therapy (NCT05370430) ... Building on these results, the trial is actively enrolling patients into expansion cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma (FL).
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for ...
Nasdaq Globe Newswire 21 May 2026
The cutaneous T-cell lymphoma clinical trial analysis report delivers important insights ...
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma (Form 8-K) (BeOne Medicines AG)
Public Technologies 15 May 2026
FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma ... "For people living with relapsed or refractory mantle cell lymphoma, each progression can bring uncertainty and questions regarding remaining treatment options.